October 17, 2008

Sirtris to Present at First Annual Boston Biotech R&D Conference

Sirtris, a GSK company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, today announced that it will provide an update on the Company's clinical and preclinical progress at the 2008 Boston Biotech R&D Conference on Wednesday, October 22, 2008 at Harvard Medical School.

Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris, a GSK company, will provide an update on the Company's lead new chemical entity (NCE) SIRT1 activator, SRT2104. Sirtris' first NCE is currently being tested in a Phase 1a clinical trial to assess safety, tolerability and pharmacokinetics of SRT2104, which is structurally unrelated to and up to 1,000 times more potent than resveratrol. Following Nature papers in 2006 and 2007 by Sirtris and academic collaborators showing lifespan extension with SIRT1 activators, and therapeutic effects in animal models of diabetes, data showing extension of healthy lifespan with an NCE will be presented. The presentation will be made at 5:40 p.m. (ET) on October 22.

"We look forward to sharing the progress of our NCE program with the Boston biotech research community," said Dr. Westphal. "Last November in the journal Nature, we reported the identification of NCEs that lower glucose and improve insulin sensitivity in preclinical models of Type 2 Diabetes. We're excited about the promising preliminary data from this clinical trial and the potential of this drug candidate as a therapy for metabolic diseases and diseases of aging."

SIRT1 is the founding member and the most widely studied of the sirtuins (SIRT 1-7), a family of enzymes that appear to control various aspects of aging and disease. In 2006, Sirtris scientists and David Sinclair, Ph.D., Sirtris Co-Founder, Scientific Advisory Board Co-Chair and Associate Professor of Pathology at Harvard Medical School, published consecutive papers in the journals Cell and Nature showing that resveratrol, a SIRT1 activator naturally found in red wine, could reduce the impact of a high fat diet, increase stamina two fold and significantly extend lifespan of mice.


Sirtris, a GSK Company, is focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that the Company believes control the aging process. Sirtris is engaged in human clinical trials for Type 2 Diabetes, and is planning similar trials in cancer, another age-related disease. Sirtris is also engaged in a human clinical trial for MELAS, a mitochondrial disorder. The company's headquarters are in Cambridge, Massachusetts. On June 5, 2008, Sirtris was acquired by GlaxoSmithKline plc for over $720 million. For more information, visit www.sirtrispharma.com.


The 2008 Boston Biotech R&D Conference will take place at Harvard Medical School and will highlight the work of top academics as well as up-and-coming biotech companies in the Boston area. The agenda features keynotes from several luminaries in medicine and research, including Jeffrey S. Flier, Dean of Harvard Medical School, Leonard Guarente, Ronald Kahn, Eric S. Lander, Robert Langer, Phillip Sharp, David Sinclair, as well as CEOs of the next generation of leading biotech and pharma companies from the Boston area. The conference is sponsored by Alexandria Real Estate Equities Inc., Pure Communications Inc., and Rodman & Renshaw, LLC. For more information, visit www.bostonbiotechconference.com.